EFFECTIVE NOVEMBER 21, 2018
CANCER ANTIGEN 27.29 TUMOR MARKER
TESTING UPDATE

Effective November 21, 2018, Wisconsin Diagnostic Laboratories (WDL) is updating tumor marker testing by replacing CA27.29 with CA15-3. This change is part of a broader effort to increase the utilization of laboratory automation and to consolidate testing instrumentation, providing improved and consistent turnaround time for test results.

- Both tests measure the same tumor marker; however, results of the current and new test are not interchangeable since different testing instrumentation is used.

Parallel testing/Re-baselining: Patients who are routinely monitored by CA27.29 will undergo a “re-baselining” process in which the current (CA27.29) and new (CA15-3) tumor markers will be measured in parallel on the same sample.

- Over a six-month period beginning November 21, 2018, CA27.29 will be reported as a comment appended to all CA15-3 results.
- CA27.29 results (reported as a comment) can be interpreted as usual to assess tumor burden.
- CA15-3 results will serve as the new baseline for ongoing assessment of tumor burden.
- Parallel testing will be performed at no cost to the patient.
- Providers are encouraged to perform tumor marker testing on patients currently being monitored by CA27.29 within the six-month period from November 21, 2018 to May 21, 2019.
- Reporting of test results will be delayed by approximately two hours during this six-month re-baselining period.

Summary:

<table>
<thead>
<tr>
<th>Current Test</th>
<th>New Test</th>
<th>Transition Period</th>
<th>Comment</th>
</tr>
</thead>
<tbody>
<tr>
<td>CA27.29</td>
<td>CA15-3</td>
<td>6 months, beginning November 21, 2018</td>
<td>CA15-3 will replace CA27.29. Both tests measure the same tumor marker but results are not interchangeable.</td>
</tr>
</tbody>
</table>

For Technical Questions or Additional Information, Please Call:
- Ian Gunsolus, PhD, Associate Director of Clinical Chemistry and Toxicology, 414.805.6972, igunsolus@mcw.edu